| Literature DB >> 24089629 |
Yuebin Ke1, Xinyun Xu, Shuang Wu, Juan Huang, Yijie Geng, Hara Misra, Yunbo Li.
Abstract
OBJECTIVE: To evaluate the potential protective effects of extracts from Fructus rhodomyrti (FR) against oxidative DNA damage using a cellular system and the antioxidant ability on potassium bromate- (KBrO3-) mediated oxidative stress in rats.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24089629 PMCID: PMC3780630 DOI: 10.1155/2013/507407
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
DNA damage of lymphocytes induced by H2O2 (n = 100).
| Treatment groups | Number of comet cells (%) | Distance of comet tail ( |
|---|---|---|
| H2O2 25 | 88.0** | 42.89 ± 9.25** |
| H2O2 50 | 100.0** | 50.45 ± 8.64** |
| H2O2 125 | 100.0** | 53.28 ± 9.58** |
|
| ||
| Control | 15.0 | 28.12 ± 6.75 |
|
|
| |
**P < 0.01 compared with the control.
The effects of FR on lymphocyte DNA damage induced by H2O2 (n = 100).
| Treatment groups | Number of comet cells (%) | Distance of comet tail ( |
|---|---|---|
| Negative (A) | 16.0 | 21.35 ± 2.54 |
| Positive (B) | 98.0 | 49.23 ± 7.27 |
| Dilution ratio of FR (1 g/mL) | ||
| 80 times (C) | 82.0* | 40.51 ± 8.33* |
| 40 times (D) | 62.0** | 35.29 ± 7.81** |
| 20 times (E) | 28.0** | 25.45 ± 4.65** |
| 10 times (F) | 45.0∗∗# | 34.36 ± 8.12** |
|
| ||
|
|
| |
*P < 0.05, **P < 0.01, compared with the positive control. # P < 0.05, compared with E group.
Figure 1The effects of FR on lymphocyte DNA damage induced by H2O2 (n = 100). (a) Negative control; (b) positive control; (c) a dilution of 80 times of FR (1 g/mL); (d) a dilution of 40 times of FR (1 g/mL); (e) a dilution of 20 times of FR (1 g/mL); (f) a dilution of 10 times of FR (1 g/mL).
The levels of hydroperoxides in plasma and tissues.
| Treatment groups | Plasma (×10−5 mM) | Kidney (mM/100 g tissue) | Liver (mM/100 g tissue) |
|---|---|---|---|
| Saline (control) | 10.26 ± 0.71 | 38.59 ± 2.43 | 43.27 ± 2.83 |
| KBrO3 (125 mg/kg body weight) | 20.38 ± 1.29△△ | 73.50 ± 5.28△△ | 63.26 ± 4.29△△ |
| FR (150 mg/kg body weight) + KBrO3 | 12.86 ± 0.83** | 59.32 ± 4.22* | 49.55 ± 3.36* |
| FR (300 mg/kg body weight) + KBrO3 | 11.60 ± 0.78** | 53.78 ± 3.73** | 46.27 ± 3.69* |
| FR (300 mg/kg body weight) alone | 10.52 ± 0.73 | 36.92 ± 2.79 | 42.65 ± 3.30 |
Values were expressed as mean ± SD, n = 6. The dose of KBrO3 was 125 mg/kg body weight in each group.
△ P < 0.05 and △△ P < 0.01 compared with the control.
*P < 0.05 and **P < 0.01 compared with KBrO3-treated rats.
The activities of SOD in hemolysate and tissues.
| Treatment groups | Hemolysate UA | Kidney UB | Liver UB |
|---|---|---|---|
| Saline (control) | 4.82 ± 0.35 | 8.64 ± 0.65 | 9.28 ± 0.62 |
| KBrO3 (125 mg/kg body weight) | 2.65 ± 0.17△△ | 5.14 ± 0.35△△ | 6.50 ± 0.45△△ |
| FR (150 mg/kg body weight) + KBrO3 | 3.48 ± 0.24* | 6.82 ± 0.44* | 7.22 ± 0.52* |
| FR (300 mg/kg body weight) + KBrO3 | 3.85 ± 0.27** | 7.37 ± 0.48** | 8.35 ± 0.56** |
| FR (300 mg/kg body weight) alone | 4.26 ± 0.32 | 8.43 ± 0.57 | 8.95 ± 0.59 |
Values were expressed as mean ± SD, n = 6. The dose of KBrO3 was 125 mg/kg body weight in each group.
UA: enzymes required for 50% inhibition of NBT reduction min/mg Hb; UB: enzymes required for 50% inhibition of NBT reduction min/mg protein.
△ P < 0.05 and △△ P < 0.01 compared with the control group.
*P < 0.05 and **P < 0.01 compared with KBrO3-treated rats.
The activities of CAT in hemolysate and tissues.
| Treatment groups | Hemolysate UA | Kidney UB | Liver UB |
|---|---|---|---|
| Saline (control) | 3.65 ± 0.27 | 22.71 ± 1.25 | 68.26 ± 3.15 |
| KBrO3 (125 mg/kg body weight) | 1.59 ± 0.13△△ | 13.23 ± 0.79△△ | 49.75 ± 2.62 |
| FR (150 mg/kg body weight) + KBrO3 | 2.86 ± 0.20* | 14.82 ± 0.82 | 60.35 ± 2.79* |
| FR (300 mg/kg body weight) + KBrO3 | 3.19 ± 0.25** | 15.37 ± 0.85 | 62.85 ± 2.80* |
| FR (300 mg/kg body weight) alone | 3.48 ± 0.31 | 21.28 ± 1.24 | 66.27 ± 3.02 |
Values were expressed as mean ± SD, n = 6. The dose of KBrO3 was 125 mg/kg body weight in each group.
UA: µ moles of H2O2 utilized/min/mg Hb; UB: µ moles of H2O2 utilized/min/mg protein.
△ P < 0.05 and △△ P < 0.01 compared with the control group.
*P < 0.05 and **P < 0.01 compared with KBrO3-treated rats.
The activities of GPx in hemolysate and tissues.
| Treatment groups | Hemolysate UA | Kidney UB | Liver UB |
|---|---|---|---|
| Saline (control) | 26.28 ± 1.52 | 10.06 ± 0.61 | 11.12 ± 0.74 |
| KBrO3 (125 mg/kg body weight) | 13.75 ± 0.94△△ | 6.15 ± 0.39△△ | 7.68 ± 0.46△△ |
| FR (150 mg/kg body weight) + KBrO3 | 17.29 ± 1.12* | 7.67 ± 0.45 | 9.10 ± 0.65* |
| FR (300 mg/kg body weight) + KBrO3 | 23.82 ± 1.50** | 8.74 ± 0.56* | 10.06 ± 0.63* |
| FR (300 mg/kg body weight) alone | 26.65 ± 1.63 | 9.82 ± 0.59 | 10.55 ± 0.70 |
Values were expressed as mean ± SD, n = 6. The dose of KBrO3 was 125 mg/kg body weight in each group.
UA: µ moles of GSH utilized/min/mg Hb; UB: µ moles of GSH utilized/min/mg protein.
△ P < 0.05 and △△ P < 0.01 compared with the control group.
*P < 0.05 and **P < 0.01 compared with KBrO3-treated rats.
The levels of GSH in plasma and tissues.
| Treatment groups | Plasma (mg/dL) | Kidney (mg/100 g tissue) | Liver (mg/100 g tissue) |
|---|---|---|---|
| Saline (control) | 35.28 ± 2.57 | 92.28 ± 5.74 | 125.72 ± 8.29 |
| KBrO3 (125 mg/kg body weight) | 20.85 ± 1.62△△ | 58.20 ± 4.12△△ | 78.27 ± 5.71△△ |
| FR (150 mg/kg body weight) + KBrO3 | 28.24 ± 1.72** | 71.39 ± 4.81* | 107.22 ± 6.26** |
| FR (300 mg/kg body weight) + KBrO3 | 31.39 ± 1.83** | 79.55 ± 5.88** | 118.82 ± 7.20** |
| FR (300 mg/kg body weight) alone | 34.20 ± 1.96 | 89.26 ± 6.26 | 126.18 ± 8.75 |
Values were expressed as mean ± SD, n = 6. The dose of KBrO3 was 125 mg/kg body weight in each group.
△ P < 0.05 and △△ P < 0.01 compared with the control group.
*P < 0.05 and **P < 0.01 compared with KBrO3-treated rats.
The levels of 8-OHdG in plasma and tissues.
| Treatment groups | Plasma (ng/mL) | Kidney (ng/mL) | Liver (ng/mL) |
|---|---|---|---|
| Saline (control) | 0.69 ± 0.08 | 1.12 ± 0.15 | 0.92 ± 0.12 |
| KBrO3 (125 mg/kg body weight) | 9.65 ± 1.26△△ | 21.65 ± 2.94△△ | 13.73 ± 2.13△△ |
| FR (150 mg/kg body weight) + KBrO3 | 5.27 ± 0.68** | 12.45 ± 1.57* | 7.82 ± 1.28** |
| FR (300 mg/kg body weight) + KBrO3 | 2.59 ± 0.23** | 3.38 ± 0.45** | 2.73 ± 0.37** |
| FR (300 mg/kg body weight) alone | 0.75 ± 0.10 | 1.05 ± 0.18 | 0.89 ± 0.15 |
Values were expressed as mean ± SD, n = 6. The dose of KBrO3 was 125 mg/kg body weight in each group.
△ P < 0.05 and △△ P < 0.01 compared with the control group.
*P < 0.05 and **P < 0.01 compared with KBrO3-treated rats.